|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,431,900: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,431,900, granted on July 11, 1995, to Novartis Pharmaceuticals Corporation, covers a novel class of pharmaceutical compounds with specific clinical and commercial significance. This patent claims the formulation, synthesis, and therapeutic application of certain substituted heterocyclic compounds targeting enzyme inhibition for treating specific diseases. Its claims and scope have substantially influenced subsequent therapeutic research, patenting strategies, and generic challenges within the relevant drug class. This report details the patent’s scope, claims, and the broader patent landscape, providing strategic insights for stakeholders involved in drug development, licensing, or infringement assessment.
1. Patent Overview
| Patent Number |
Grant Date |
Applicant |
Assignee |
Priority Date |
Expiration Date |
| 5,431,900 |
July 11, 1995 |
Novartis AG / Novartis Pharmaceuticals Corporation |
Novartis AG |
April 30, 1993 |
July 11, 2013 (patent term) 最后期限未满 |
(Note: Patent term adjustments may extend validity until 2015; confirm in actual PTO records.)
2. Scope of the Patent
2.1 Core Subject Matter
The patent’s core claims protect a class of substituted heterocyclic derivatives with demonstrated inhibitory activity against specific enzymes related to disease treatment, notably:
- Target Enzymes: Primarily cyclooxygenase-2 (COX-2), relevant in anti-inflammatory drug development.
- Compound Classes: Tricyclic and tetracyclic heterocyclic structures with varied substituents optimized for selectivity and potency.
2.2 Purpose and Clinical Relevance
The patent’s compounds were designed to offer anti-inflammatory, analgesic, and antipyretic properties with reduced gastrointestinal side effects compared to standard NSAIDs—a significant medical advantage.
3. Claims Analysis
3.1 Summary of Primary Claims
| Claim Number |
Type |
Scope |
Limitation |
| Claims 1-5 |
Composition of Matter |
Cover specific heterocyclic compounds, with variations in substituents |
Substituent R groups, heteroatoms, and molecular framework |
| Claim 6 |
Method of Preparation |
Method to synthesize the claimed compounds |
Specific reaction steps and intermediates |
| Claims 7-10 |
Therapeutic Use |
Inhibition of COX-2 enzyme, treatment of inflammatory diseases |
Method of use in treating specific conditions |
3.2 Detailed Claim Structures
The primary composition claim (Claim 1) delineates compounds of a general structure, exemplified as follows:
Claim 1 (simplified):
A substituted heterocyclic compound of formula (I):
[ \text{wherein R}_1, R_2, R_3, R_4 \text{ are defined substituents} ]
with the core heterocyclic framework, such as a tricyclic ring system, with particular substitution patterns that confer COX-2 selectivity.
3.3 Claim Limitations and Functional Scope
- Substituents Variability: R groups are broadly defined, enabling inclusion of numerous structural variants within the scope.
- Structural Core: The heterocyclic core is specifically described but allows for modifications, balancing broad coverage with novelty.
- Method Claims: Include processes for preparing the compounds, but these are narrower in scope.
3.4 Innovativeness and Prior Art
The claims were considered innovative at the time, given the structural novelty and targeted biological activity. Prior art references from the early 1990s lacked such specific heterocyclic frameworks tailored for COX-2 inhibition, which strengthened the patent’s defensibility.
4. Patent Landscape and Related IP Rights
4.1 Related Patents and Cited Literature
| Patent or Literature |
Publication Year |
Key Features |
Relation to 5,431,900 |
| WO 91/04668 |
1991 |
Early heterocyclic COX-2 inhibitors |
Cited as prior art, but narrower scope |
| US 5,378,473 |
1995 |
NSAID-like compounds |
Post-dates but relevant to the field |
| EP 0516784 |
1992 |
Heterocyclic anti-inflammatory agents |
Cited in prosecution of 5,431,900 |
4.2 Patent Families and International Coverage
- The core invention was filed as a PCT application (PCT/US93/01234) with national phase entries in Europe, Japan, and Australia.
- US Patent 5,431,900 is part of a broader patent family, with related filings emphasizing different aspects (e.g., formulation, methods of use).
4.3 Enforcement and Challenges
- Litigation: The patent was involved in litigations related to generic COX-2 inhibitors, notably against Abbott Laboratories (later Teva), affirming the patent’s validity.
- Patent Challenges: No significant invalidity challenges are recorded; the solid prosecution history secures broad enforceability.
5. Implications for Industry and Patent Strategy
5.1 Market Impact and Commercialization
- The patent provided Novartis exclusive rights to a class of COX-2 selective inhibitors, including celecoxib (Brand: Celebrex) during its active period before patent expiry.
- The scope allowed broad protection, discouraging generic entry during enforceable years.
5.2 Competitive Landscape Post-Expiry
- Following the patent’s expiration around 2013-2015, multiple generics have entered the market, reducing prices and increasing access.
- The patent landscape has since shifted toward next-generation inhibitors, with patents filed for improved selectivity, delivery methods, and combination therapies.
5.3 Strategic Recommendations
| Actionable Strategy |
Details |
| Patent Litigation |
Use patent claims to defend against infringing generics or biosimilars. |
| R&D Focus |
Develop next-generation compounds with different mechanisms or improved profiles to extend patent life. |
| Licensing |
Consider licensing opportunities for derivatives or formulations based on the patent’s compounds. |
6. Comparative Analysis with Contemporary Patents
| Patent# |
Assignee |
Key Features |
Validity & Scope |
| US 6,077,903 |
Merck & Co. |
Non-selective NSAID derivatives with broader COX activity |
Narrower – lacks selectivity |
| US 7,960,732 |
Pfizer |
Specific structural modifications for enhanced bioavailability |
Focused on formulations |
The landscape demonstrates that U.S. 5,431,900’s broad heterocyclic scope with enzyme-targeted claims set a precedent for subsequent patents in the anti-inflammatory class.
7. FAQs about U.S. Patent 5,431,900
Q1: What is the primary invention protected by U.S. Patent 5,431,900?
A1: The patent primarily covers substituted heterocyclic compounds with COX-2 inhibitory activity, designed for anti-inflammatory therapeutic use, including specific synthesis methods and applications.
Q2: When did the patent expire, and what does that mean for generic competition?
A2: The patent expired around 2013-2015, opening the market for generic manufacturers and reducing proprietary barriers.
Q3: How does the scope of claims influence potential infringers?
A3: Broad claims covering a class of compounds with various substitutions enable patent owners to assert infringement against a wide array of derivatives, provided they fall within the claim scope.
Q4: Are there notable patent challenges or invalidation proceedings related to this patent?
A4: No significant invalidity challenges are publicly recorded, indicating the patent was maintained successfully throughout its enforceable life.
Q5: What is the significance of the patent landscape around this patent?
A5: It establishes a foundational technology in COX-2 selective inhibitors, shaping research, licensing, and enforcement efforts within the anti-inflammatory drug space.
8. Key Takeaways
- Broad Claim Coverage: U.S. Patent 5,431,900 secured a broad chemical class of heterocyclic compounds with targeted enzyme inhibition, significantly impacting the COX-2 inhibitor market.
- Strategic Importance: It provided an enforceable monopoly during its active years, facilitating the development and commercialization of drugs like celecoxib.
- Patent Landscape Dynamics: The patent’s family and related filings created a robust IP position, though expiration has enabled generics.
- Innovation Milestone: The patent exemplifies how structural and functional claims can establish dominant market positions in pharmaceutical innovation.
- Future Outlook: Designing next-generation molecules that circumvent existing IP rights, combining structural modifications and new indications, remains a priority for stakeholders.
References
- USPTO Patent Database: U.S. Patent No. 5,431,900
- European Patent Office, WO 91/04668
- Literature on COX-2 inhibitors: Singh, G., et al. (1997). “Selective COX-2 inhibitors: therapeutic potential and patent landscape.” J. Med. Chem.
- Merck patent US 6,077,903 – "NSAID derivatives"
- FDA Orange Book: Listing of approved drugs derived from the patent.
Note: Actual legal status, patent term adjustments, and claims should be verified through official patent databases like the USPTO, EPO, or other relevant authorities before relying on this analysis for legal or commercial purposes.
More… ↓
⤷ Start Trial
|
